Navegando por Palavras-chave "mlh1"

Agora exibindo 1 - 1 de 1
  • Nenhuma Miniatura disponível
    Item
    Somente Metadadados
    Imunoexpressão dos biomarcadores ts, cox-2, egfr, msh6, mlh1 no adenocarcinoma colorretal e sua correlação com o grau de diferenciação tumoral e os fatores prognósticos
    (Universidade Federal de São Paulo (UNIFESP), 2013-09-25) Batista, Wilson Roberto [UNIFESP]; Matos, Delcio Matos [UNIFESP]; Universidade Federal de São Paulo (UNIFESP)
    Objective: To study the immunoexpression of biomarkers TS, p53, COX2, EGFR, MSH6, MLH1 in patients with colorectal carcinoma, correlating with the degree of tumor differentiation and clinical prognostic factors patolólogicos. Methods: We analyzed tissues fixed in formalin and embedded in paraffin blocks of tumors from 107 patients, for immunohistochemistry by the streptavidin-biotin method using the technique of matrix arrangement of tissue samples (tissue-microarray). In the evaluation of positive markers was used categorical scores that determined the cutoff value in the percentage of stained tumor cells. Tissue expression of the proteins were correlated with the variables of degree of cell differentiation, staging, disease-free, recurrence, survival and specific mortality. We employed the Fisher exact test (Agresti, 1990) to study the association between tumor grade and TS, Cox-2, EGFR, MSH1, MSH6 and p53, and tumor staging correlated with TS, Cox-2, EGFR, MSH1, MSH6 and p53. Estimation of Kaplan-Meier (Collett, 2003), Log-rank test (Collett, 2003) and adjusting the Cox regression model (Cox, 1972) to investigate the behavior of the overall survival of patients (months) according to TS, COX-2, EGFR, MSH6, MLH1 and p53 and disease-free interval of subjects (months), according to TS, COX-2, EGFR, MSH6, MLH1 and p53. Results: The degree of tumor differentiation of individuals is not associated with TS (p = 0.138), COX-2 (p = 0.428), EGFR (p = 0.103), MSH6 (p = 0.876), MLH1 (p = 0.792) and p53 (p = 0.884). The staging is not associated with TS (p = 0.817), COX-2 (p = 0.842), EGFR (p = 0.344), MSH6 (p = 0.923) and p53 (p = 0.666). The same behavior was not observed for MLH1 (p = 0.021) in which the group of patients with stage III or IV is a higher percentage of MLH1 negative (27.4%) than in the group of patients with stage 0, I, or II (2.2%). The survival time of individuals is not related to TS (p = 0.480), COX-2 (p = 0.998), EGFR (p = 0.600), MSH6 (p = 0.318), MLH1 (p = 0.798) and p53 (p = 0.695). The disease-free interval of subjects is not related to TS (p = 0.356), COX-2 (p = 0.885), EGFR (p = 0.786), MSH6 (p = 0.178), MLH1 (p = 0.691) and p53 (p = 0.441). Conclusion: There was no correlation of the association between the degree of tumor differentiation, staging, survival time and disease-free interval with markers TS, p53, COX2, EGFR, MSH6. In advanced cases of RCC with stage III and IV, there was a higher percentage of MLH1 negative.